Page last updated: 2024-10-25

cl 387785 and Glioblastoma

cl 387785 has been researched along with Glioblastoma in 1 studies

CL 387785: structure in first source
N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide : A member of the class of quinazolines that is 4,6-diaminoquinazoine in which the one of the hydrogens attached to the amino group at position 4 has been replaced by a m-bromophenyl group while one of the hydrogens attached to the amino group at position 6 has been replaced by a but-2-ynoyl group.

Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rao, RD1
Mladek, AC1
Lamont, JD1
Goble, JM1
Erlichman, C1
James, CD1
Sarkaria, JN1

Other Studies

1 other study available for cl 387785 and Glioblastoma

ArticleYear
Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells.
    Neoplasia (New York, N.Y.), 2005, Volume: 7, Issue:10

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Carrier Proteins; Cell Cycle

2005